Mon, Mar 2, 2015, 10:58 AM EST - U.S. Markets close in 5 hrs 2 mins

Recent

% | $
Quotes you view appear here for quick access.

Endocyte, Inc. (ECYT) Message Board

  • alternatepatel alternatepatel Mar 31, 2013 2:28 PM Flag

    ~200mn$ cash, then why $125M Mixed Securities Shelf ?

    i am long, but can't understand this, they have plenty of cash and i think they would never run out of cash at least for 2 years from now, then why do they need 125mn$ mixed shelf? what does that mean? please help

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • seriousjust, sunshinecamesoftly, sudhanva_n

      your comments are very helpful,
      i am surprised by the scarcity of retail investors here on the board, may be thats good for us

      ecyt is highly undervalued

      • 1 Reply to alternatepatel
      • ECYT has great potential. The recent analyst day presentation is a must listen (and the slides). Another good source for ECYT is to follow David Sobek in twitter. The year end cash is expected to be 145-160 million. If MRK starts phase 1 on TNBC or EMA approves the PROC drug, ECYT gets lots of Moola.

        ECYT has given rights to only Vintafolide to MRK - Rest of the pipe line like Vintafolatide (Diagnostic), Tubylysin, PSMA and everything else is owned by ECYT.

        In preclinical Tubulysin has proved to be much more potent than VIntafolide. The PSMA diagnostic looks good too.

        This company platform will be worth a lot.

        Sentiment: Strong Buy

    • they might not need it for vintafolide, not even, for the FR++ 1.000.000 patients a year, and billions of revenue, for which Endocyte, and they will receive another $880 mln in milenstone, besides split revenue in future

      but they can better upspeed pipeline, and this will be huge, Tubulysin, might be even bigger, and expect a partnership also

      look at MDVN, they have cap of over 3 BLN, and , much less potential

      though i doubt, they will need this soon, it is better to time it upfront, probalby will be spread in tho units

      in case of BIO, best news, this ride should go over $17, and never look back again, ... I am in for 3, 4, 6, 9, amd 10 and will add till it goes over 50, not sure, but I think it will go steep in direct line up now, as this is future of BIO

    • sunshinecamesoftly2002 sunshinecamesoftly2002 Mar 31, 2013 10:16 PM Flag

      Companies put up a shelf offering so they have the option of financing open should the need arise. ECYT has plenty of money and at present and anticipated financial needs they have a several year runway. SItuations can arise (such as the purchase of a competitor) where having cash available is an added asset.
      Presently the biggest challenge for ECYT will be to get rolling the research and expedite the development of their substantial assets

    • Administrative purposes

      Sentiment: Strong Buy

 
ECYT
6.09+0.29(+5.00%)10:58 AMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.